Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Update

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 153,000 shares, an increase of 25.5% from the October 15th total of 121,900 shares. Based on an average daily volume of 258,900 shares, the short-interest ratio is presently 0.6 days. Currently, 0.5% of the company’s shares are sold short.

Coeptis Therapeutics Trading Down 3.2 %

Shares of Coeptis Therapeutics stock traded down $0.01 on Friday, hitting $0.20. The stock had a trading volume of 59,360 shares, compared to its average volume of 282,862. The stock has a 50 day moving average of $0.19 and a 200 day moving average of $0.24. The firm has a market capitalization of $8.18 million, a P/E ratio of -0.69 and a beta of -0.94. Coeptis Therapeutics has a twelve month low of $0.15 and a twelve month high of $1.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.55 and a current ratio of 0.40.

Coeptis Therapeutics (NASDAQ:COEP) last posted its earnings results on Friday, August 16th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Sell-side analysts expect that Coeptis Therapeutics will post -0.26 earnings per share for the current fiscal year.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.